BACKGROUND/AIMS: The effect of basiliximab induction therapy on long-term patient and graft survival is not yet clear. We aimed to evaluate if there is any advantage of routine basiliximab induction on the long-term outcome of living related donor kidney transplantation. METHODS:One hundred adult recipients with their first kidney allograft were randomized into two treatment groups, one group received basiliximab and the second served as a control. All patients received a maintenance triple immunosuppressive therapy (steroids, cyclosporine (CsA) micro-emulsion and azathioprine) and were followed up thoroughly for 7 years. RESULTS:Basiliximab significantly reduced the proportion of patients who experienced acute rejection in the first year (18/50) when compared to the control group (31/50), and in 7 years (28/50) when compared to (37/50) in controls. The cumulative steroid dose used throughout the whole study period was significantly lower in the basiliximab group. The overall incidence of post-transplant complications was comparable among the two treatment groups. There was no significant difference in patient or graft survival; 7 years patient and graft survival were 92, 76% for basiliximab and 92, 80% for the control group, respectively. CONCLUSION: Routine basiliximab induction significantly reduced the incidence of acute rejection without any noticeble beneficial effect on the long-term renal transplantation outcome.
RCT Entities:
BACKGROUND/AIMS: The effect of basiliximab induction therapy on long-term patient and graft survival is not yet clear. We aimed to evaluate if there is any advantage of routine basiliximab induction on the long-term outcome of living related donor kidney transplantation. METHODS: One hundred adult recipients with their first kidney allograft were randomized into two treatment groups, one group received basiliximab and the second served as a control. All patients received a maintenance triple immunosuppressive therapy (steroids, cyclosporine (CsA) micro-emulsion and azathioprine) and were followed up thoroughly for 7 years. RESULTS:Basiliximab significantly reduced the proportion of patients who experienced acute rejection in the first year (18/50) when compared to the control group (31/50), and in 7 years (28/50) when compared to (37/50) in controls. The cumulative steroid dose used throughout the whole study period was significantly lower in the basiliximab group. The overall incidence of post-transplant complications was comparable among the two treatment groups. There was no significant difference in patient or graft survival; 7 years patient and graft survival were 92, 76% for basiliximab and 92, 80% for the control group, respectively. CONCLUSION: Routine basiliximab induction significantly reduced the incidence of acute rejection without any noticeble beneficial effect on the long-term renal transplantation outcome.
Authors: C Ponticelli; A Yussim; V Cambi; C Legendre; G Rizzo; M Salvadori; D Kahn; S H Kashi; K Salmela; L Fricke; J Garcia-Martinez; R Lechler; U Heemann; F Monteon; J Ortuño; J J Amenabar; M Arias; M L Nicholson; H Sperschneider; D Abendroth; C Gracida; M Lao; M S Sever; N Lameire; A Sanchez-Fructuoso; A Bascì; G Segoloni; J Connolly; P Altieri; J Akoh; H Prestele; D Girault Journal: Transplant Proc Date: 2001 Feb-Mar Impact factor: 1.066
Authors: D C Brennan; K Flavin; J A Lowell; T K Howard; S Shenoy; S Burgess; S Dolan; J M Kano; M Mahon; M A Schnitzler; R Woodward; W Irish; G G Singer Journal: Transplantation Date: 1999-04-15 Impact factor: 4.939
Authors: Hussein A Sheashaa; Mohamed A Bakr; Amany M Ismail; Osama E Gheith; Khalid F El-dahshan; Mohamed A Sobh; Mohamed A Ghoneim Journal: Am J Nephrol Date: 2005-05-19 Impact factor: 3.754
Authors: H A Bock; H Gallati; R M Zürcher; M Bachofen; M J Mihatsch; J Landmann; G Thiel Journal: Transplantation Date: 1995-03-27 Impact factor: 4.939
Authors: Angela C Webster; Lorenn P Ruster; Richard McGee; Sandra L Matheson; Gail Y Higgins; Narelle S Willis; Jeremy R Chapman; Jonathan C Craig Journal: Cochrane Database Syst Rev Date: 2010-01-20